Latest filings (excl ownership)
8-K
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
24 Jun 24
S-8
Registration of securities for employees
24 May 24
8-K
Departure of Directors or Certain Officers
14 May 24
10-Q
2024 Q1
Quarterly report
10 May 24
8-K
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
10 May 24
EFFECT
Notice of effectiveness
8 Apr 24
DEFA14A
Additional proxy soliciting materials
2 Apr 24
DEF 14A
Definitive proxy
2 Apr 24
S-3
Shelf registration
29 Mar 24
PRE 14A
Preliminary proxy
22 Mar 24
10-K
2023 FY
Annual report
22 Mar 24
8-K
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
22 Mar 24
8-K
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
18 Mar 24
D
Exempt offering of security
5 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Feb 24
424B5
Prospectus supplement for primary offering
30 Jan 24
8-K
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
30 Jan 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
8-K
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
18 Dec 23
EFFECT
Notice of effectiveness
27 Nov 23
CORRESP
Correspondence with SEC
21 Nov 23
UPLOAD
Letter from SEC
21 Nov 23
S-3
Shelf registration
17 Nov 23
S-8
Registration of securities for employees
17 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
13 Nov 23
8-K
Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
3 Oct 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
14 Aug 23
8-K
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
31 Jul 23
424B5
Prospectus supplement for primary offering
31 Jul 23
8-K
55% objective response rate; 23% complete response rate in locally advanced cSCC
27 Jul 23
8-K
Departure of Directors or Certain Officers
13 Jun 23
424B5
Prospectus supplement for primary offering
24 May 23
8-K
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
24 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
15 May 23
EFFECT
Notice of effectiveness
8 May 23
EFFECT
Notice of effectiveness
8 May 23
EFFECT
Notice of effectiveness
8 May 23
Latest ownership filings
4
WILLIAM GARRETT GRAY
24 May 24
4
James F Oliviero III
24 May 24
3
Initial statement of insider ownership
24 May 24
SC 13D/A
Fortress Biotech, Inc.
17 May 24
4
MICHAEL S WEISS
16 May 24
4
Sharma Amit
16 May 24
4
BARRY M SALZMAN
16 May 24
4
LINDSAY A MD ROSENWALD
16 May 24
4
Neil Herskowitz
16 May 24
4
Christian Bechon
16 May 24
SC 13D/A
Fortress Biotech, Inc.
22 Mar 24
4
Change in insider ownership
22 Mar 24
3
Sharma Amit
19 Mar 24
4
James F Oliviero III
1 Mar 24
4
WILLIAM GARRETT GRAY
1 Mar 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
4
WILLIAM GARRETT GRAY
2 Feb 24
4
James F Oliviero III
2 Feb 24
5
James F Oliviero III
2 Feb 24
4
Change in insider ownership
3 Jan 24
SC 13D/A
Fortress Biotech, Inc.
26 Sep 23
4
Change in insider ownership
26 Sep 23
SC 13D/A
Fortress Biotech, Inc.
6 Jul 23
4
Change in insider ownership
3 Jul 23
4
MICHAEL S WEISS
15 Jun 23
4
BARRY M SALZMAN
15 Jun 23
4
LINDSAY A MD ROSENWALD
15 Jun 23
4
Neil Herskowitz
15 Jun 23
4
Scott Boilen
15 Jun 23
4
Christian Bechon
15 Jun 23
SC 13D/A
Fortress Biotech, Inc.
19 Apr 23
4
James F Oliviero III
4 Apr 23
4
WILLIAM GARRETT GRAY
4 Apr 23
4
Change in insider ownership
4 Apr 23
4
James F Oliviero III
3 Mar 23
4
WILLIAM GARRETT GRAY
3 Mar 23
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
4
WILLIAM GARRETT GRAY
3 Feb 23
4
James F Oliviero III
3 Feb 23
SC 13D/A
Fortress Biotech, Inc.
13 Jan 23